Cara Therapeutics to Participate in September Medical Meetings
August 31 2017 - 8:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced upcoming CR845
presentations at PAINWeek, to be held September 5-9, 2017 in Las
Vegas, NV and the American Association of Nurse Anesthetists (AANA)
Nurse Anesthesia Annual Congress, to be held September 8-12, 2017
in Seattle, WA. Presentations will include clinical trial
data for CR845, Cara’s first-in-class peripherally selective kappa
opioid agonist being developed for the treatment of acute and
chronic pain, as well as chronic kidney disease-associated
pruritus.
PAINWeekDetails for the
presentations are as follows:
CR845 Poster Presentation:
Poster Title:
|
|
"A Phase 2, Randomized,
Double-Blind, Placebo-Controlled, Titration-to-Effect Study of
Orally Administered CR845 in Patients with Osteoarthritis of theHip
or Knee" |
Poster
Number: |
|
101 |
Date/
Time: |
|
Thursday, September 7,
2017; 6:30-8:30 p.m. PT |
Satellite Symposium:
Presentation
Title: |
|
"A Potential New Path of
Pain Relief: Time for a Change with a Peripherally Acting Kappa
Opioid Receptor Agonist (KORA)" |
Date/
Time: |
|
Friday, September 8, 2017;
12:30 - 1:30 p.m. PT |
Moderator: |
|
Joseph Stauffer,
D.O., M.B.A., Chief Medical Officer, Cara
Therapeutics |
Faculty: |
|
Michael J.
Brennan, M.D., Medical Director, the Pain Center of
Fairfield; Senior Attending Physician, Department of Medicine,
Bridgeport Hospital;Associate Director, Chronic Pain and Recovery
Program, Silver Hill Hospital |
For information about PAINWeek, visit
http://www.painweek.org/.
AANA Nurse Anesthesia Annual
CongressDetails for the satellite symposium are as
follows:
Presentation
Title: |
|
"A Potential New Path of
Pain Relief" |
Date/
Time: |
|
Sunday, September 10,
2017; 4:00 – 5:00 p.m. PT |
Speakers: |
|
Jackie Rowles,
D.N.P., M.B.A., C.R.N.A., A.N.P.-B.C., D.A.A.P.M.,
F.A.A.N., Director, DNP Nurse Anesthesia Program, Marian
University; Associate Professor, Leighton School of Nursing;
Clinical Instructor, College of Osteopathic Medicine; Adjunct
Faculty, Nurse Anesthesia Pain Management Fellowship, Texas
Christian University |
|
|
|
|
|
Joseph Stauffer,
D.O., M.B.A., Chief Medical Officer, Cara
Therapeutics |
For information about AANA, visit
http://aana2017.com/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates, led
by CR845, that target the body's peripheral nervous system. CR845
has demonstrated initial efficacy in patients with
moderate-to-severe pain, without inducing many of the undesirable
side effects typically associated with currently available pain
therapeutics. In patients with moderate-to-severe CKD-associated
pruritus, CR845 has demonstrated its potential to reduce itch and
improve quality of life.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024